LBD
SAGE

Landsberg Bennett & Dubbaneh’s Sage Therapeutics SAGE Stock Holding History

Landsberg Bennett & Dubbaneh’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,805
Closed -$487K – 218
2019
Q4 		$487K Buy
+6,805
New +$837K 0.11% 170

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Landsberg Bennett & Dubbaneh's SAGE Position: Q1 2020 in Review

Landsberg Bennett & Dubbaneh sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 6,805 shares — an estimated $487K sold.

Landsberg Bennett & Dubbaneh first reported a position in SAGE in Q4 2019 and held it in 1 quarter. The position peaked at $487K in Q4 2019. 229 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

  • Landsberg Bennett & Dubbaneh reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Landsberg Bennett & Dubbaneh sold 6,805 Sage Therapeutics shares in Q1 2020, an estimated $487K.
  • Landsberg Bennett & Dubbaneh first reported a position in Sage Therapeutics in Q4 2019 and held it in 1 quarter.
  • Landsberg Bennett & Dubbaneh's Sage Therapeutics position peaked at $487K in Q4 2019.
  • 229 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Landsberg Bennett & Dubbaneh's 13F filing for Q1 2020, filed 21 Apr 2020.